TY - JOUR AU - D.M. Kulkarni AU - S.L. Nilekar AU - Vidhya Thirumalaisamy PY - 2020/02/29 Y2 - 2024/03/28 TI - Association of biofilm production in ESBL and MBL producing clinical isolates of Pseudomonas aeruginosa JF - Tropical Journal of Pathology and Microbiology JA - Trop J Pathol Microbiol VL - 6 IS - 2 SE - Original Article DO - 10.17511/jopm.2020.i02.10 UR - https://pathology.medresearch.in/index.php/jopm/article/view/423 AB - Introduction: Pseudomonas aeruginosa is one of the most prevalent nosocomial pathogens that cause a life-threatening infection. One of the important characteristics of P. aeruginosa is biofilm formation and the most studied bacterium related to biofilm formation so far. The biofilm formation and beta-lactamases production synergistically contribute to the extensive dissemination of multi-drug resistant strains.Aim: The present study was conducted to identify, biofilm-producing isolates of P. aeruginosa along with their antibiotic resistance pattern and ESBL and MBL production and to analyze their antibiogram.Materials and methods: Various clinical specimens were collected and totally 82 clinical isolates of P. aeruginosa were included in this study. Biofilm producing isolates were identified by the tube adherence method.Results: Among the total, 22 [26.83%] isolates were biofilm producers and the maximum number was obtained from blood [100%], followed by ETT [75%], and Drain [66.67%]. Biofilm producing isolates were showing more resistance in comparison to non-biofilm producers. All isolates of P. aeruginosa were sensitive to colistin and polymyxin B. Association of ESBL production and biofilm formation found to be statistically significant [p < 0.002], which was a contrast to association of MBL production and biofilm formation.Conclusion: High-level resistance to antimicrobial agents is a characteristic feature of infection caused by biofilm and lead to chronic infections. Knowledge about these biofilm-producing isolates is important in the clinical setting to eradicate these chronic and life-threating infections. ER -